@inproceedings{oai:repo.qst.go.jp:00085334,
 author = {Watanabe, Sumiyo and Hayashi, Kotaro and Tho, Kayoko and Kim, Hunjin and Chaya, Hiroyuki and Fukushima, Shigeto and Keisuke Katsushima and Kondo, Yutaka and Ogura, Satomi and Cabral, Horacio and Kensuke, Osada and Nishiyama, Nobuhiro and Miyata, Kanjiro and Kataoka, Kazunori and Kensuke, Osada},
 book = {Cancer Science},
 month = {Jan},
 note = {There are critical issues in siRNA therapeutics, as follows, 1) siRNA is immediately degraded in extracellular milieu, such as bloodstream, 2)
the size of siRNA is -5nm, so siRNA is readily excreted from the kidney to the urine, and 3) the negative charge of siRNA repels the negatively
charged cell membrane, inhibiting the cellular uptake of siRNA. Thus, many previous studies have encapsulated siRNA into -100 nm-sized
nanoparticles to stabilize it. However, refractory cancers have tight barriers that prevent the penetration of such nanoparticles into cancer
cells. To overcome these hurdles, a new type of siRNA nanocarrier is developed for the cancer-targeted siRNA delivery, using a Y-shaped
block catiomer (YBC) with precisely regulated chain length and precisely neutralize their charges. Indeed, two YBCs are bound to a single
siRNA in the bloodstream, generating a dynamic polyin-pair, termed uPIC. Owing to both high stability in the bloodstream and ultra-small
(or optimal) size (-18 nm) to penetrate fibrotic tissues, uPIC efficiently delivers siRNA into murine models of fibrotic pancreatic cancer and
glioblastoma, exerting the significant anticancer activity in vivo.},
 title = {Unit polyion complex (uPIC) nanocarrier for siRNA delivery to glioblastoma and pancreatic cancer, Cancer Science},
 volume = {112},
 year = {2022}
}